vs
EXELIXIS, INC.（EXEL）与REPLIGEN CORP（RGEN）财务数据对比。点击上方公司名可切换其他公司
EXELIXIS, INC.的季度营收约是REPLIGEN CORP的3.0倍（$598.7M vs $197.9M）。EXELIXIS, INC.净利率更高（40.8% vs 6.7%，领先34.1%）。REPLIGEN CORP同比增速更快（13.6% vs 5.6%）。EXELIXIS, INC.自由现金流更多（$332.4M vs $17.6M）。过去两年EXELIXIS, INC.的营收复合增速更高（18.7% vs 14.4%）
Exelixis是一家总部位于美国加利福尼亚州阿拉米达的基因组学药物研发企业，专注于创新抗肿瘤药物开发，旗下产品Cometriq已获美国FDA批准用于治疗甲状腺髓样癌，在其余多种转移性癌症治疗领域也已展现出良好临床活性。
Repligen是一家全球生命科学企业，专注于创新生物工艺技术与系统的研发及商业化，助力提升生物药生产效率。公司1981年成立，总部位于美国马萨诸塞州沃尔瑟姆，于纳斯达克挂牌上市，股票代码RGEN，截至2025年全球员工超1900人，主要服务生物制药领域客户。
EXEL vs RGEN — 直观对比
营收规模更大
EXEL
是对方的3.0倍
$197.9M
营收增速更快
RGEN
高出8.0%
5.6%
净利率更高
EXEL
高出34.1%
6.7%
自由现金流更多
EXEL
多$314.8M
$17.6M
两年增速更快
EXEL
近两年复合增速
14.4%
损益表 — Q4 2026 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $598.7M | $197.9M |
| 净利润 | $244.5M | $13.3M |
| 毛利率 | 95.6% | 52.5% |
| 营业利润率 | 39.3% | 9.0% |
| 净利率 | 40.8% | 6.7% |
| 营收同比 | 5.6% | 13.6% |
| 净利润同比 | 74.8% | 143.9% |
| 每股收益（稀释后） | $0.89 | $0.24 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EXELRGEN
| Q1 26 | $598.7M | — | ||
| Q4 25 | $597.8M | $197.9M | ||
| Q3 25 | $568.3M | $188.8M | ||
| Q2 25 | $555.4M | $182.4M | ||
| Q1 25 | $566.8M | $169.2M | ||
| Q4 24 | — | $174.1M | ||
| Q3 24 | $539.5M | $154.9M | ||
| Q2 24 | $637.2M | $154.1M |
净利润EXELRGEN
| Q1 26 | $244.5M | — | ||
| Q4 25 | $193.6M | $13.3M | ||
| Q3 25 | $184.8M | $14.9M | ||
| Q2 25 | $159.6M | $14.9M | ||
| Q1 25 | $139.9M | $5.8M | ||
| Q4 24 | — | $-30.3M | ||
| Q3 24 | $118.0M | $-654.0K | ||
| Q2 24 | $226.1M | $3.3M |
毛利率EXELRGEN
| Q1 26 | 95.6% | — | ||
| Q4 25 | 96.9% | 52.5% | ||
| Q3 25 | 96.6% | 53.2% | ||
| Q2 25 | 96.5% | 50.0% | ||
| Q1 25 | 96.5% | 53.6% | ||
| Q4 24 | — | 26.1% | ||
| Q3 24 | 96.8% | 50.0% | ||
| Q2 24 | 97.2% | 49.8% |
营业利润率EXELRGEN
| Q1 26 | 39.3% | — | ||
| Q4 25 | 39.6% | 9.0% | ||
| Q3 25 | 37.6% | 8.9% | ||
| Q2 25 | 33.6% | 7.6% | ||
| Q1 25 | 28.8% | 3.9% | ||
| Q4 24 | — | -17.7% | ||
| Q3 24 | 25.2% | -5.1% | ||
| Q2 24 | 43.3% | 1.0% |
净利率EXELRGEN
| Q1 26 | 40.8% | — | ||
| Q4 25 | 32.4% | 6.7% | ||
| Q3 25 | 32.5% | 7.9% | ||
| Q2 25 | 28.7% | 8.2% | ||
| Q1 25 | 24.7% | 3.4% | ||
| Q4 24 | — | -17.4% | ||
| Q3 24 | 21.9% | -0.4% | ||
| Q2 24 | 35.5% | 2.2% |
每股收益（稀释后）EXELRGEN
| Q1 26 | $0.89 | — | ||
| Q4 25 | $0.69 | $0.24 | ||
| Q3 25 | $0.65 | $0.26 | ||
| Q2 25 | $0.55 | $0.26 | ||
| Q1 25 | $0.47 | $0.10 | ||
| Q4 24 | — | $-0.55 | ||
| Q3 24 | $0.40 | $-0.01 | ||
| Q2 24 | $0.77 | $0.06 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.1B | $767.6M |
| 总债务越低越好 | — | $542.2M |
| 股东权益账面价值 | $2.2B | $2.1B |
| 总资产 | $2.8B | $2.9B |
| 负债/权益比越低杠杆越低 | — | 0.26× |
8季度趋势，按日历期对齐
现金及短期投资EXELRGEN
| Q1 26 | $1.1B | — | ||
| Q4 25 | $988.5M | $767.6M | ||
| Q3 25 | $791.1M | $748.7M | ||
| Q2 25 | $1.0B | $708.9M | ||
| Q1 25 | $1.1B | $697.2M | ||
| Q4 24 | — | $757.4M | ||
| Q3 24 | $1.2B | $784.0M | ||
| Q2 24 | $1.0B | $809.1M |
总债务EXELRGEN
| Q1 26 | — | — | ||
| Q4 25 | — | $542.2M | ||
| Q3 25 | — | $537.9M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $525.6M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
股东权益EXELRGEN
| Q1 26 | $2.2B | — | ||
| Q4 25 | $2.2B | $2.1B | ||
| Q3 25 | $2.0B | $2.1B | ||
| Q2 25 | $2.1B | $2.1B | ||
| Q1 25 | $2.2B | $2.0B | ||
| Q4 24 | — | $2.0B | ||
| Q3 24 | $2.3B | $2.0B | ||
| Q2 24 | $2.1B | $2.0B |
总资产EXELRGEN
| Q1 26 | $2.8B | — | ||
| Q4 25 | $2.8B | $2.9B | ||
| Q3 25 | $2.7B | $2.9B | ||
| Q2 25 | $2.8B | $2.9B | ||
| Q1 25 | $2.9B | $2.9B | ||
| Q4 24 | — | $2.8B | ||
| Q3 24 | $3.0B | $2.8B | ||
| Q2 24 | $2.8B | $2.9B |
负债/权益比EXELRGEN
| Q1 26 | — | — | ||
| Q4 25 | — | 0.26× | ||
| Q3 25 | — | 0.26× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.27× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $333.5M | $25.7M |
| 自由现金流经营现金流 - 资本支出 | $332.4M | $17.6M |
| 自由现金流率自由现金流/营收 | 55.5% | 8.9% |
| 资本支出强度资本支出/营收 | 0.2% | 4.1% |
| 现金转化率经营现金流/净利润 | 1.36× | 1.93× |
| 过去12个月自由现金流最近4个季度 | $875.8M | $93.9M |
8季度趋势，按日历期对齐
经营现金流EXELRGEN
| Q1 26 | $333.5M | — | ||
| Q4 25 | $290.3M | $25.7M | ||
| Q3 25 | $49.0M | $48.1M | ||
| Q2 25 | $211.4M | $28.6M | ||
| Q1 25 | $240.3M | $15.0M | ||
| Q4 24 | — | $39.2M | ||
| Q3 24 | $271.3M | $49.3M | ||
| Q2 24 | $119.5M | $42.2M |
自由现金流EXELRGEN
| Q1 26 | $332.4M | — | ||
| Q4 25 | $288.8M | $17.6M | ||
| Q3 25 | $46.2M | $43.4M | ||
| Q2 25 | $208.5M | $21.5M | ||
| Q1 25 | $236.3M | $11.4M | ||
| Q4 24 | — | $33.6M | ||
| Q3 24 | $263.1M | $42.3M | ||
| Q2 24 | $113.0M | $37.4M |
自由现金流率EXELRGEN
| Q1 26 | 55.5% | — | ||
| Q4 25 | 48.3% | 8.9% | ||
| Q3 25 | 8.1% | 23.0% | ||
| Q2 25 | 37.5% | 11.8% | ||
| Q1 25 | 41.7% | 6.8% | ||
| Q4 24 | — | 19.3% | ||
| Q3 24 | 48.8% | 27.3% | ||
| Q2 24 | 17.7% | 24.3% |
资本支出强度EXELRGEN
| Q1 26 | 0.2% | — | ||
| Q4 25 | 0.2% | 4.1% | ||
| Q3 25 | 0.5% | 2.5% | ||
| Q2 25 | 0.5% | 3.9% | ||
| Q1 25 | 0.7% | 2.1% | ||
| Q4 24 | — | 3.2% | ||
| Q3 24 | 1.5% | 4.5% | ||
| Q2 24 | 1.0% | 3.1% |
现金转化率EXELRGEN
| Q1 26 | 1.36× | — | ||
| Q4 25 | 1.50× | 1.93× | ||
| Q3 25 | 0.27× | 3.23× | ||
| Q2 25 | 1.32× | 1.92× | ||
| Q1 25 | 1.72× | 2.57× | ||
| Q4 24 | — | — | ||
| Q3 24 | 2.30× | — | ||
| Q2 24 | 0.53× | 12.70× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
